Corcept Therapeutics Incorporated (CORT) Social Stream
CORCEPT THERAPEUTICS INC (CORT) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering CORCEPT THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-04 | 4 | $35 | $16 | $24.75 | $23.45 | 5.54% |
| 2022-01-26 | 4 | $35 | $16 | $25.5 | $23.45 | 8.74% |
| 2022-01-28 | 5 | $35 | $16 | $26.4 | $23.45 | 12.58% |
| 2022-02-02 | 6 | $35 | $16 | $27 | $23.45 | 15.14% |
| 2022-04-19 | 6 | $35 | $16 | $27.166 | $23.45 | 15.85% |
| 2022-05-06 | 6 | $35 | $16 | $26.833 | $23.45 | 14.43% |
| 2022-07-13 | 6 | $35 | $16 | $28.8 | $23.45 | 22.81% |
| 2022-07-27 | 6 | $35 | $16 | $29.833 | $23.45 | 27.22% |
| 2022-08-01 | 6 | $35 | $16 | $29.833 | $23.45 | 27.22% |
| 2022-08-04 | 6 | $45 | $16 | $32.166 | $23.45 | 37.17% |
| 2022-11-07 | 6 | $45 | $18 | $32.5 | $23.45 | 38.59% |
| 2022-12-02 | 6 | $45 | $18 | $32.166 | $23.45 | 37.17% |
| 2022-12-09 | 6 | $45 | $18 | $31.666 | $23.45 | 35.04% |
| 2022-12-20 | 6 | $44 | $18 | $31.5 | $23.45 | 34.33% |
| 2023-02-14 | 6 | $44 | $18 | $29.333 | $23.45 | 25.09% |
| 2023-03-01 | 6 | $44 | $18 | $29 | $23.45 | 23.67% |
| 2023-03-28 | 6 | $44 | $18 | $28.666 | $23.45 | 22.24% |
| 2023-04-04 | 7 | $44 | $18 | $28.428 | $23.45 | 21.23% |
| 2023-05-04 | 6 | $44 | $18 | $28 | $23.45 | 19.4% |
| 2023-05-26 | 8 | $44 | $18 | $27.75 | $23.45 | 18.34% |
| 2023-07-25 | 7 | $44 | $18 | $27.75 | $23.45 | 18.34% |
| 2023-08-03 | 7 | $44 | $18 | $29 | $23.45 | 23.67% |
| 2023-08-04 | 7 | $47.5 | $18 | $29.687 | $23.45 | 26.6% |
| 2023-08-25 | 8 | $47.5 | $18 | $29.812 | $23.45 | 27.13% |
| 2023-10-19 | 8 | $47.5 | $18 | $30.312 | $23.45 | 29.26% |
| 2023-11-02 | 8 | $50 | $18 | $31.25 | $23.45 | 33.26% |
| 2023-11-07 | 7 | $50 | $20 | $34.428 | $23.45 | 46.81% |
| 2023-12-13 | 6 | $50 | $27 | $37 | $23.45 | 57.78% |
The Trend in the Analyst Price Target
Over the past 12 months, CORT's average price target has gone up $5.5.
CORT reports an average of 24.19% for its upside potential over the past 43 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-01 | 6 | 44.0 | 18 | 29.000 | 19.86 | 46.02% |
| 2023-04-11 | 8 | 44.0 | 18 | 28.000 | 22.06 | 26.93% |
| 2023-05-26 | 8 | 44.0 | 18 | 27.750 | 23.98 | 15.72% |
| 2023-10-19 | 8 | 47.5 | 18 | 30.312 | 28.00 | 8.26% |
| 2023-11-07 | 6 | 50.0 | 20 | 34.428 | 25.74 | 33.75% |
CORT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 15 months, CORT's average broker recommendation rating improved by 0.5.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how CORCEPT THERAPEUTICS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -2543.19% of that group.
- To contextualize these metrics, consider that out of all US stocks, CORCEPT THERAPEUTICS INC's number of analysts covering the stock is higher than 986.98% of them.
- In terms of how CORCEPT THERAPEUTICS INC fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 837.62% of that group.
- In terms of how CORCEPT THERAPEUTICS INC fares relative to stocks in the mid market cap category, note that its average analyst price target is higher than 1358.62% of that group.
In the Pharmaceutical Products industry, INVA, ACAD, and PTCT are the three stocks most similar to CORCEPT THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for CORT? Use POWR Ratings for clearer insight into price direction.